Susquehanna International Group
LYEL icon

Susquehanna International Group’s Lyell Immunopharma LYEL Stock Holding History

Susquehanna International Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,400
Closed -$259K – 13707
2025
Q4 		$259K Buy
+8,400
New +$188K ﹤0.01% 10298

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's LYEL Position: Q1 2026 in Review

Susquehanna International Group increased its Lyell Immunopharma (LYEL) stake by 105% in Q1 2026, buying an estimated $3.72M and bringing the position to 310,198 shares worth $6.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3862.

Susquehanna International Group first reported a position in LYEL in Q3 2021 and has held it in 16 quarters since. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Susquehanna International Group held 310,198 shares of Lyell Immunopharma worth $6.22M as of Q1 2026.
  • Susquehanna International Group bought 159,182 Lyell Immunopharma shares in Q1 2026, an estimated $3.72M.
  • Lyell Immunopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3862 holding.
  • Susquehanna International Group first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 16 quarters since.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.